In NSCLC, clinical trials are evaluating drugs targeting multiple immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3 (HAVCR2), VISTA (VSIR), CD40, and GITR (TNFRSF18), as well as combinations of immune checkpoint inhibitors and other targets. The gene discussed is CD40; the disease is non-small cell lung carcinoma.